Kyowa Hakko Kirin China Pharmaceutical

Kyowa Kirin China is the regional subsidiary of the Japanese specialty pharmaceutical group Kyowa Kirin, focusing on the development and commercialization of innovative therapies within China. The company's portfolio is centered on nephrology, oncology, and rare diseases, featuring key products like Crysvita for X-linked hypophosphatemia and Nesp for renal anemia. Operating with a headquarters and manufacturing base in Shanghai, the company integrates local production with global R&D to address unmet medical needs in the Chinese healthcare market. It has established a significant presence in the Chinese market through strategic partnerships and a robust commercial infrastructure. The company continues to expand its pipeline with recent approvals such as Poteligeo for rare hematologic malignancies.